MA42692A - Compositions biopharmaceutiques - Google Patents

Compositions biopharmaceutiques

Info

Publication number
MA42692A
MA42692A MA042692A MA42692A MA42692A MA 42692 A MA42692 A MA 42692A MA 042692 A MA042692 A MA 042692A MA 42692 A MA42692 A MA 42692A MA 42692 A MA42692 A MA 42692A
Authority
MA
Morocco
Prior art keywords
biopharmaceutical compositions
biopharmaceutical
compositions
Prior art date
Application number
MA042692A
Other languages
English (en)
Inventor
Narendra B Bam
Jennifer Dally
Myrna A Monck
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA42692A publication Critical patent/MA42692A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA042692A 2015-08-24 2016-08-22 Compositions biopharmaceutiques MA42692A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MA42692A true MA42692A (fr) 2018-07-04

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042692A MA42692A (fr) 2015-08-24 2016-08-22 Compositions biopharmaceutiques

Country Status (22)

Country Link
US (10) US10870695B2 (fr)
EP (2) EP4056590A1 (fr)
JP (4) JP6821659B2 (fr)
KR (2) KR20180037275A (fr)
CN (5) CN116327923A (fr)
AU (1) AU2016311385C1 (fr)
BR (1) BR112018003741A2 (fr)
CA (1) CA2996088A1 (fr)
CL (1) CL2018000499A1 (fr)
CO (1) CO2018001840A2 (fr)
CR (1) CR20180115A (fr)
DO (1) DOP2018000057A (fr)
EA (1) EA037487B1 (fr)
IL (1) IL257539A (fr)
MA (1) MA42692A (fr)
MX (2) MX2018002319A (fr)
PE (1) PE20181176A1 (fr)
PH (1) PH12018500379A1 (fr)
TW (2) TWI750133B (fr)
UY (1) UY36868A (fr)
WO (1) WO2017033121A1 (fr)
ZA (1) ZA201801158B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037487B1 (ru) 2015-08-24 2021-04-02 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Биофармацевтические композиции
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11111292B2 (en) 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
UY37747A (es) * 2017-05-26 2019-01-02 Glaxosmithkline Ip Dev Ltd Composiciones para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
TWI801425B (zh) 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
WO2019224724A1 (fr) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Compositions biopharmaceutiques comprenant des variants d'anticorps
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
CA3164600A1 (fr) * 2019-12-18 2021-06-24 Tesaro, Inc. Compositions biopharmaceutiques et procedes associes
CN118251407A (zh) * 2021-09-22 2024-06-25 索诺玛生物治疗公司 Il5ra细胞表面标记物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR248044A1 (es) 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ATE346867T1 (de) 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (fr) 2005-05-30 2007-01-03 Jerini AG Antagonistes du recepteur C5a
SI1988910T1 (en) 2006-02-28 2018-02-28 Kodiak Sciences Inc. Polymeric conjugates containing acryloyloxyethylphosphorylcholine and their preparations
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CN104650235A (zh) * 2007-11-30 2015-05-27 葛兰素集团有限公司 抗原结合构建体
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
DK2524693T3 (da) 2010-01-14 2014-08-25 Sanwa Kagaku Kenkyusho Co Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet
KR20140044305A (ko) 2011-02-09 2014-04-14 글락소스미스클라인 엘엘씨 동결건조된 제제
EA201391488A1 (ru) 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
KR20140066124A (ko) 2011-04-07 2014-05-30 글락소스미스클라인 엘엘씨 점도가 감소된 제제
EP2738172A1 (fr) 2012-11-28 2014-06-04 Almirall, S.A. Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
WO2014158231A1 (fr) * 2013-03-14 2014-10-02 Abbvie Inc. Compositions d'espèces faiblement acides et leurs procédés de production et d'utilisation
WO2014141149A1 (fr) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations présentant une viscosité réduite
EP2848615A1 (fr) 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
EP3052092A2 (fr) 2013-10-02 2016-08-10 Vectura Limited Procédé et appareil
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
BR112016018116A2 (pt) 2014-02-06 2018-02-20 Arsanis Biosciences Gmbh anticorpo e sequências específicos para e. coli, preparação farmacêutica ou para diagnóstico compreendendo os mesmos, uso do anticorpo para tratar infecção por e. coli e diagnosticar a doença, ácido nucleico que codifica o anticorpo, um cassete de expressão, plasmídeo ou célula hospedeira compreendendo o mesmo, e método de produção
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
EA037487B1 (ru) 2015-08-24 2021-04-02 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Биофармацевтические композиции

Also Published As

Publication number Publication date
TWI750133B (zh) 2021-12-21
US20180251539A1 (en) 2018-09-06
TWI780988B (zh) 2022-10-11
US11459384B2 (en) 2022-10-04
AU2016311385C1 (en) 2019-08-22
EP4056590A1 (fr) 2022-09-14
US11299541B2 (en) 2022-04-12
JP7463070B2 (ja) 2024-04-08
CN116327923A (zh) 2023-06-27
IL257539A (en) 2018-04-30
EP3341409A1 (fr) 2018-07-04
CN116474091A (zh) 2023-07-25
TW202233238A (zh) 2022-09-01
JP2024123040A (ja) 2024-09-10
US20220185878A1 (en) 2022-06-16
CN116327922A (zh) 2023-06-27
AU2016311385B2 (en) 2019-05-09
CA2996088A1 (fr) 2017-03-02
US20220380452A1 (en) 2022-12-01
PH12018500379A1 (en) 2018-09-03
MX2018002319A (es) 2018-04-11
CN108137683A (zh) 2018-06-08
EA037487B1 (ru) 2021-04-02
JP2022023049A (ja) 2022-02-07
JP6821659B2 (ja) 2021-01-27
CR20180115A (es) 2018-04-12
JP2020033351A (ja) 2020-03-05
US11286298B2 (en) 2022-03-29
US20240294629A1 (en) 2024-09-05
US20200199219A1 (en) 2020-06-25
KR20240099511A (ko) 2024-06-28
US20210340247A1 (en) 2021-11-04
ZA201801158B (en) 2019-08-28
US20240294628A1 (en) 2024-09-05
US20210332125A1 (en) 2021-10-28
DOP2018000057A (es) 2018-03-15
JP2018526369A (ja) 2018-09-13
UY36868A (es) 2017-03-31
KR20180037275A (ko) 2018-04-11
AU2016311385A1 (en) 2018-03-15
US11274148B2 (en) 2022-03-15
US20240294630A1 (en) 2024-09-05
CL2018000499A1 (es) 2018-07-06
PE20181176A1 (es) 2018-07-20
TW201722473A (zh) 2017-07-01
WO2017033121A1 (fr) 2017-03-02
MX2024001617A (es) 2024-03-06
US10870695B2 (en) 2020-12-22
CO2018001840A2 (es) 2018-05-31
CN116327921A (zh) 2023-06-27
US20210340246A1 (en) 2021-11-04
EA201890572A1 (ru) 2018-10-31
BR112018003741A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
DK3361870T3 (da) Fungicidsammensætninger
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
MA42692A (fr) Compositions biopharmaceutiques
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
DK3597189T3 (da) Krystallinske forbindelser
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3316857T3 (da) Multifasiske sammensætninger
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DK3274482T3 (da) Stenborsknop
DK3393254T3 (da) Sammensætning
DK3318308T3 (da) Badmintonketsjer
DE112015005906A5 (de) Gurtschlossbringer
DK3528791T3 (da) Dispergible sammensætninger
DE112016005599A5 (de) Strahlungsgrill